Dialysis and transplantation have transformed the lives of people with serious kidney disease. But that does not mean it is “job done”. Individuals who need dialysis have significantly reduced life expectancy, especially if they must remain on it for a long time, while there is a shortage of donor kidneys – and transplantation carries its own problems. In this latest Optimum Perspectives podcast, three experts who are all developing new treatments for various aspects of kidney disease, share their thoughts. Stephen Adams hosts the episode, which features Renée Aguiar-Lucander, CEO of Hansa Biopharma; Krishna Polu, CEO of R1 Therapeutics; and Thomas Kledal, CEO of Synklino.
","author_name":"Optimum Strategic Communications"}